Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ANIKA THERAPEUTICS, INC.

(ANIK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/14/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
34.21(c) 33.64(c) 33.52(c) 33.01(c) 31.99(c) Last
112 912 98 204 110 846 65 811 120 814 Volume
+0.50% -1.67% -0.36% -1.52% -3.09% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 144 M - -
Net income 2021 5,78 M - -
Net cash position 2021 107 M - -
P/E ratio 2021 70,6x
Yield 2021 -
Sales 2022 163 M - -
Net income 2022 5,41 M - -
Net cash position 2022 99,4 M - -
P/E ratio 2022 204x
Yield 2022 -
Capitalization 462 M 462 M -
EV / Sales 2021 2,47x
EV / Sales 2022 2,22x
Nbr of Employees 277
Free-Float -
More Financials
Company
Anika Therapeutics, Inc. is a joint preservation company. The Company creates and delivers advancements in early intervention orthopedic care, including in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. It is focused on developing, manufacturing, and commercializing products based on its hyaluronic acid (HA) technology platform.... 
Sector
Pharmaceuticals
Calendar
02/23Earnings Release
More about the company
Ratings of Anika Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about ANIKA THERAPEUTICS, INC.
2021Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
2021ANIKA THERAPEUTICS : Piper Sandler Healthcare Conference Presentation
PU
2021Anika to Participate in Upcoming Investor Conferences
GL
2021Stephens Starts Anika Therapeutics at Overweight With $55 Price Target
MT
2021ANIKA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Creation of a Direc..
AQ
2021Anika Therapeutics, Inc. Enters into Third Amendment to Credit Agreement Amending its E..
CI
2021Barrington Adjusts Price Target on Anika Therapeutics to $48 From $44, Keeps Outperform..
MT
2021Tranche Update on Anika Therapeutics, Inc.'s Equity Buyback Plan announced on May 2, 20..
CI
2021ANIKA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION A..
AQ
2021ANIKA : Q3 Earnings Snapshot
AQ
2021Earnings Flash (ANIK) ANIKA THERAPEUTICS Posts Q3 EPS $0.05, vs. Street Est of $-0.01
MT
2021Earnings Flash (ANIK) ANIKA THERAPEUTICS Reports Q3 Revenue $39.5M, vs. Street Est of $..
MT
2021Revenue growth of 25% year-over-yearCompany revises revenue growth outlook for 2021 to ..
PU
2021Anika Therapeutics, Inc. Revises Revenue Guidance for the Fiscal Year 2021
CI
2021Anika Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months..
CI
More news
News in other languages on ANIKA THERAPEUTICS, INC.
2021Earnings Flash (ANIK) ANIKA THERAPEUTICS annonce un chiffre d'affaires de 39,5 millions..
2021Anika Therapeutics, Inc. révise ses prévisions de revenus pour l'année fiscale 2021
2021Anika Therapeutics obtient une autorisation supplémentaire de la FDA pour l'utilisation..
2021Earnings Flash (ANIK) ANIKA THERAPEUTICS affiche un chiffre d'affaires de 38,1 millions..
2021Anika Therapeutics, Inc. révise ses prévisions de bénéfices pour l'année 2021
More news
Analyst Recommendations on ANIKA THERAPEUTICS, INC.
More recommendations
Chart ANIKA THERAPEUTICS, INC.
Duration : Period :
Anika Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ANIKA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 31,99 $
Average target price 50,75 $
Spread / Average Target 58,6%
EPS Revisions
Managers and Directors
Cheryl Renee Blanchard President, Chief Executive Officer & Director
Michael L. Levitz Chief Financial Officer, Treasurer & EVP
Jeffery S. Thompson Chairman
Mira Leiwant VP-Quality, Regulatory & Clinical Affairs
Steven W. Ek Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ANIKA THERAPEUTICS, INC.-10.72%462
CSL LIMITED-9.01%91 245
WUXI BIOLOGICS (CAYMAN) INC.-3.19%48 492
SAMSUNG BIOLOGICS CO.,LTD.-9.41%45 433
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-8.09%32 393